Recombinant Research: Breaking open rewards and incentives

Can open data dominate biological science as open source has in software?

To move from a hothouse environment of experimentation to the mainstream of one of the world's most lucrative and tradition-bound industries, Sage Bionetworks must aim for its nucleus: rewards and incentives. Comparisons to open source software and a summary of tasks for Sage Congress.

Comment |

Recombinant Research: Sage Congress plans for patient engagement

The Vioxx problem is just one instance of the wider malaise afflicting the drug industry. Managers from major pharma companies expressed confidence that they could expand public or "pre-competitive" research in the direction Sage Congress proposed. The sector left to engage is the one that's central to all this work–the public.

Comment |

Recombinant Research: Sage Congress promotes data sharing in genetics

Report from a movement that believes in open source and open data in science

Through two days of demos, keynotes, panels, and breakout sessions, Sage Congress brought its vision to a high-level cohort of 230 attendees from universities, pharmaceutical companies, government health agencies, and others who can make change in the field.

Comment |

Collaborative genetics, part 5: Next steps for genetic commons

The final installment of this series, about a Sage Commons Congress on
the open-source sharing of genetic research, looks at what Sage
Bionetworks and its friends need to do.

Comment: 1 |